ArticleThoracic cancer2019
CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Prognostic role of CRABP2 in lung cancer: a meta-analysis.Journal of cardiothoracic surgery · 2024Pooled it
- Circular RNAs in NSCLC: Their Role in Tumorigenesis, Tumor Microenvironment Reshaping, and Response to Therapies.Cancers · 2026Review
- E3 ubiquitin-ligase Hakai regulates LRP4 stability and Wnt/β-catenin signalling in colorectal cancer cells.iScience · 2026Article
- Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai.Cellular & molecular biology letters · 2025Review
- Article
- Differentiating malignant and benign pleural effusion in patients with lung cancer: anFrontiers in oncology · 2023Article
- The roles of RNA NHeliyon · 2022Review
- Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.BMC bioinformatics · 2022Article
- Emerging role of N6-methyladenosine RNA methylation in lung diseases.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells.Medical oncology (Northwood, London, England) · 2022Article
- Analysis of N6-Methyladenosine RNA Methylation Regulators in Diagnosis and Distinct Molecular Subtypes of Ankylosing Spondylitis.Disease markers · 2022Article
- The development of a novel signature based on the mFrontiers in genetics · 2022Article
- Identification and experimental validation of key m6A modification regulators as potential biomarkers of osteoporosis.Frontiers in genetics · 2022Article
- Clinical and molecular significance of the RNA mFrontiers in genetics · 2022Article
- MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates.Cancer cell international · 2021Article
- N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.Biomarker research · 2021Article
- Regulation of Epithelial-Mesenchymal Plasticity by the E3 Ubiquitin-Ligases in Cancer.Cancers · 2020Review
- Silencing of CD276 suppresses lung cancer progression by regulating integrin signaling.Journal of thoracic disease · 2020Article
- Heat Shock Protein 90 Chaperone Regulates the E3 Ubiquitin-Ligase Hakai Protein Stability.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown that E3 ubiquitin ligase CBLL1 plays multiple roles in development and tumorigenesis. CBLL1 is over-expressed in colon cancer and associated with cancer cell proliferation. While, the overexpression of CBLL1 inhibited the estrogenic dependent cell proliferation and migration in ER alpha dependent breast cancer cell MCF-7.
methodsWe used an immunohistochemical method to detect CBLL1 expression in human NSCLC and corresponding normal lung tissues and analyzed its relationship with clinicopathological parameters. Moreover, we investigated the role of CBLL1 in NSCLC cell behavior by inhibiting its expression in A549 and H1299 cells.
resultsIn this study, we found that CBLL1 was frequently upregulated in non-small lung cancer (NSCLC) tissues compared to the adjacent nontumor tissues. We found that the high expression of CBLL1 was associated with the tumor size in NSCLC tissues. It has been recently reported that CBLL1 promotes cell proliferation and invasion in A549 and H460 cells. Our results confirmed that CBLL1 promoted the proliferation by promoting G1/S cell cycle transition in NSCLCs cells. Moreover, CBLL1 knockdown inhibited cell invasion via increased E-cadherin protein expression, and decreased expression of MMP2 and MMP9 in NSCLC cell lines. The protein expression of E-cadherin was increased after CBLL1 depletion while the E-cadherin mRNA was not affected after knockdown of the endogenous CBLL1.
conclusionThese results provide important insights for using CBLL1 as an oncogenic marker gene in the development and progression of non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.